Company Analysis Zoetis
1. Summary
Advantages
- The stock's return over the last year (-5.54%) is higher than the sector average (-31.87%).
- Current debt level 46.3% is below 100% and has decreased over 5 years from 57.23%.
- The company's current efficiency (ROE=46.91%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (173.88 $) is higher than fair price (64.57 $)
- Dividends (0.9431%) are below the sector average (1.32%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Zoetis | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.1% | -2.2% | -1.4% |
| 90 days | -0.4% | -33.2% | 0.8% |
| 1 year | -5.5% | -31.9% | 21.5% |
ZTS vs Sector: Zoetis has outperformed the "Healthcare" sector by 26.33% over the past year.
ZTS vs Market: Zoetis has significantly underperformed the market by -27.03% over the past year.
Stable price: ZTS is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ZTS with weekly volatility of -0.1066% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (173.88 $) is higher than the fair price (64.57 $).
Price is higher than fair: The current price (173.88 $) is 62.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (38.45) is lower than that of the sector as a whole (114.5).
P/E vs Market: The company's P/E (38.45) is lower than that of the market as a whole (70.26).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (18.06) is higher than that of the sector as a whole (9.44).
P/BV vs Market: The company's P/BV (18.06) is lower than that of the market as a whole (22.61).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (10.55) is higher than that of the sector as a whole (4.13).
P/S vs Market: The company's P/S indicator (10.55) is lower than that of the market as a whole (15.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (26.66) is higher than that of the sector as a whole (17.79).
EV/Ebitda vs Market: The company's EV/Ebitda (26.66) is higher than that of the market as a whole (24.37).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 8.59% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (8.59%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-57.12%).
5.4. ROE
ROE vs Sector: The company's ROE (46.91%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (46.91%) is higher than that of the market as a whole (18.07%).
5.5. ROA
ROA vs Sector: The company's ROA (16.41%) is higher than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (16.41%) is higher than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (19.69%) is higher than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (19.69%) is higher than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.9431% is below the average for the sector '1.32%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.9431% has been steadily paid over the past 7 years, DSI=1.
Dividend growth: Company's dividend yield 0.9431% has been growing over the last 5 years. Growth over 15 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (29.52%) are at a comfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 15.09.2023 | Chen Heidi C. Executive Vice President |
Sale | 180.15 | 1 784 390 | 9 905 |
| 10.06.2022 | Reed Willie M Director |
Sale | 162.31 | 301 085 | 1 855 |
| 23.12.2021 | Lagano Roxanne Executive Vice President |
Sale | 241.7 | 317 836 | 1 315 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
